157 related articles for article (PubMed ID: 21069410)
1. The effects of raloxifene on bone turnover markers and bone mineral density in women on maintenance hemodialysis.
Saito O; Saito T; Asakura S; Sugase T; Ito C; Ando Y; Muto S; Kusano E
Clin Exp Nephrol; 2011 Feb; 15(1):126-31. PubMed ID: 21069410
[TBL] [Abstract][Full Text] [Related]
2. Effects of raloxifene on bone metabolism in hemodialysis patients with type 2 diabetes.
Saito O; Saito T; Asakura S; Akimoto T; Inoue M; Ando Y; Muto S; Kusano E
Int J Endocrinol Metab; 2012; 10(2):464-9. PubMed ID: 23843805
[TBL] [Abstract][Full Text] [Related]
3. Effects of raloxifene on bone mineral metabolism in postmenopausal Japanese women on hemodialysis.
Tanaka M; Itoh K; Matsushita K; Matsushita K; Moriishi M; Kawanishi H; Fukagawa M
Ther Apher Dial; 2011 Jun; 15 Suppl 1():62-6. PubMed ID: 21595855
[TBL] [Abstract][Full Text] [Related]
4. Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis.
Hernández E; Valera R; Alonzo E; Bajares-Lilue M; Carlini R; Capriles F; Martinis R; Bellorin-Font E; Weisinger JR
Kidney Int; 2003 Jun; 63(6):2269-74. PubMed ID: 12753317
[TBL] [Abstract][Full Text] [Related]
5. Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal women.
Weinstein RS; Parfitt AM; Marcus R; Greenwald M; Crans G; Muchmore DB
Osteoporos Int; 2003 Oct; 14(10):814-22. PubMed ID: 14610642
[TBL] [Abstract][Full Text] [Related]
6. Effects of raloxifene on bone metabolism in postmenopausal women on chronic hemodialysis.
Nagatoya K; Nishimoto K; Shibahara N; Takahashi T; Kanehara H; Ueno N; Yasuda H; Okada S; Ueda H; Hirai K; Inoue T;
Clin Exp Nephrol; 2015 Oct; 19(5):939-46. PubMed ID: 25504368
[TBL] [Abstract][Full Text] [Related]
7. Association between baseline values of bone turnover markers and bone mineral density and their response to raloxifene treatment in Japanese postmenopausal women with osteoporosis.
Majima T; Shimatsu A; Komatsu Y; Satoh N; Fukao A; Ninomiya K; Matsumura T; Nakao K
Endocr J; 2008 Mar; 55(1):41-8. PubMed ID: 18187874
[TBL] [Abstract][Full Text] [Related]
8. Three-month changes in bone turnover markers and bone mineral density response to raloxifene in Japanese postmenopausal women with osteoporosis.
Majima T; Shimatsu A; Satoh N; Komatsu Y; Fukao A; Ninomiya K; Matsumura T; Nakao K
J Bone Miner Metab; 2008; 26(2):178-84. PubMed ID: 18301975
[TBL] [Abstract][Full Text] [Related]
9. Comparison of effects of alendronate and raloxifene on lumbar bone mineral density, bone turnover, and lipid metabolism in elderly women with osteoporosis.
Iwamoto J; Sato Y; Uzawa M; Takeda T; Matsumoto H
Yonsei Med J; 2008 Feb; 49(1):119-28. PubMed ID: 18306478
[TBL] [Abstract][Full Text] [Related]
10. Early changes in biochemical markers of bone turnover predict bone mineral density response to antiresorptive therapy in Korean postmenopausal women with osteoporosis.
Kim SW; Park DJ; Park KS; Kim SY; Cho BY; Lee HK; Shin CS
Endocr J; 2005 Dec; 52(6):667-74. PubMed ID: 16410657
[TBL] [Abstract][Full Text] [Related]
11. Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis: a multi-center, randomized, placebo-controlled clinical trial.
Liu JL; Zhu HM; Huang QR; Zhang ZL; Li HL; Qin YJ; Zhang Y; Wei DL; Lu JH; Liu H; Chen XP; Liu YJ; Ekangaki A; Zheng YM; Diez-Perez A; Harper K
Chin Med J (Engl); 2004 Jul; 117(7):1029-35. PubMed ID: 15265377
[TBL] [Abstract][Full Text] [Related]
12. Raloxifene ameliorates progressive bone loss in postmenopausal dialysis patients with controlled parathyroid hormone levels.
Eriguchi R; Umakoshi J; Miura S; Sato Y
Clin Nephrol; 2009 Dec; 72(6):423-9. PubMed ID: 19954718
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of 1-year treatment with raloxifene on bone and lipid metabolism in Japanese postmenopausal women with osteoporosis.
Majima T; Komatsu Y; Shimatsu A; Satoh N; Fukao A; Ninomiya K; Matsumura T; Nakao K
Endocr J; 2007 Dec; 54(6):855-62. PubMed ID: 17917307
[TBL] [Abstract][Full Text] [Related]
14. The benefits of estrogen or selective estrogen receptor modulator on kidney and its related disease-chronic kidney disease-mineral and bone disorder: osteoporosis.
Lee WL; Cheng MH; Tarng DC; Yang WC; Lee FK; Wang PH
J Chin Med Assoc; 2013 Jul; 76(7):365-71. PubMed ID: 23664736
[TBL] [Abstract][Full Text] [Related]
15. Effects of arzoxifene on bone, lipid markers, and safety parameters in postmenopausal women with low bone mass.
Downs RW; Moffett AM; Ghosh A; Cox DA; Dowsett SA; Harper K
Osteoporos Int; 2010 Jul; 21(7):1215-26. PubMed ID: 19798460
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis.
Dane C; Dane B; Cetin A; Erginbas M
Gynecol Endocrinol; 2007 Jul; 23(7):398-403. PubMed ID: 17701771
[TBL] [Abstract][Full Text] [Related]
17. Effect of raloxifene on parathyroid hormone in osteopenic and osteoporotic postmenopausal women with chronic kidney disease stage 5.
Haghverdi F; Farbodara T; Mortaji S; Soltani P; Saidi N
Iran J Kidney Dis; 2014 Nov; 8(6):461-6. PubMed ID: 25362221
[TBL] [Abstract][Full Text] [Related]
18. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
Ozmen B; Kirmaz C; Aydin K; Kafesciler SO; Guclu F; Hekimsoy Z
Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083
[TBL] [Abstract][Full Text] [Related]
19. Effect of raloxifene hydrochloride on bone mineral density and bone turnover in Kuwaiti postmenopausal women with osteoporosis.
Abdelazim IA; Abdelrazak KM; Al-Kadi M; Yehia AH; Nusair BM; Faza MA
Arch Osteoporos; 2014; 9():189. PubMed ID: 25037077
[TBL] [Abstract][Full Text] [Related]
20. Systematic review of raloxifene in postmenopausal Japanese women with osteoporosis or low bone mass (osteopenia).
Fujiwara S; Hamaya E; Sato M; Graham-Clarke P; Flynn JA; Burge R
Clin Interv Aging; 2014; 9():1879-93. PubMed ID: 25395843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
